42 reports

  • 3.3.1 DRIVERS AND OPPORTUNITIES
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE

TUBERCULOSIS (TB) INCIDENCE IS MUCH HIGHER IN BIG CITIES.

  • Respiratory Disease
  • World
  • Market Size
  • Medtronic, Inc.
  • ResMed Inc.

Respiratory disorders such as asthma, interstitial lung disease (ILD), tuberculosis (TB), chronic obstructive pulmonary disease (COPD), and pneumonia are on the rise.

  • Respiratory Disease
  • Boston Scientific Corporation
  • Broncus Medical Inc.
  • Medtronic, Inc.
  • Olympus Corporation
  • ANTHONISEN NR (2005). LUNG HEALTH STUDY RESEARCH GROUP. ANN INTERN MED; 142(4): 233-239
  • PELAIA G, ET AL. (2012). THE POTENTIAL OF BIOLOGICS FOR THE TREATMENT OF ASTHMA. NATURE DRUG DISCOVERY; 11: 958-972

THE PULMONOLOGIST MAY ALSO ASK FOR A SKIN TEST TO DETERMINE THE PRESENCE OF TUBERCULOSIS.

  • Respiratory Disease
  • World
  • Market Size
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • IMPORTANT CAUSES OF DEATH AND DISABILITY DURING THE PAST TWO DECADES SINCE 2011
  • Respiratory Disease
  • World
  • Market Size
  • Astra Group
  • Becton Property Group
  • COPD Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
  • COPD Therapeutics Market, Global, All Pipeline Products, Discovery, 2017

Clinical characteristics of patients with tuberculosis-destroyed lung.

  • Respiratory Disease
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • ASTHMA
  • GROWING INCIDENCE OF CHRONIC RESPIRATORY DISEASES

This device is mainly used for people with pulmonary tuberculosis, which is a highly infectious disease.

  • Respiratory Disease
  • World
  • Market Size
  • CareFusion Corporation
  • Teleflex Incorporated

Produces diagnostic devices for respiratory viruses, tuberculosis, hepatitis, and cervical cancer.

  • Respiratory Disease
  • World
  • Alere Inc.
  • CareFusion Corporation
  • Nihon Kohden Corporation

CHEST X-RAY MAY SHOW ENLARGED LUNGS, IRREGULAR AIR POCKETS (BULLAE), OR A FLATTENED DIAPHRAGM, AND CAN HELP RULE OUT OTHER DISEASES, SUCH AS LUNG CANCER AND TUBERCULOSIS.

  • Respiratory Disease
  • Demand
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Sunovion Pharmaceuticals Inc.
  • SOURCES NOT USED FOR COPD ANALYSES IN THE US, JAPAN, FIVE MAJOR EU MARKETS, AND CHINA
  • SOURCES NOT USED FOR COPD ANALYSES IN THE US, JAPAN, FIVE MAJOR EU MARKETS, AND CHINA

Furthermore, asthma and tuberculosis cases were excluded.

  • Respiratory Disease
  • Asia
  • Europe
  • Japan
  • World

2016-2020 TECHNAVIO.

  • Respiratory Disease
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • 9.2.6 JAPAN

Egyptian Journal of Chest Diseases and Tuberculosis; ##: ##-## Reed CE (1999).

  • Respiratory Disease
  • World
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Novartis AG

TUBERCULOSIS AND RESPIRATORY DISEASES GLAXOSMITHKLINE PLC ## MAR 2009 ## MAR 2010 ## ## ## ## BETA ## ADRENERGIC RECEPTOR (BETA ## ADRENORECEPTOR OR ADRB##) AGONIST; GLUCOCORTICOID RECEPTOR (GR OR NUCLEAR RECEPTOR SUBFAMILY ## GROUP C MEMBER ## OR NR##C##) AGONIST BETA ## ADRENERGIC RECEPTOR (BETA

  • Hospital
  • Respiratory Disease
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc

Placebo, in Patients with Moderate-to-severe COPD with Destroyed Lung by Tuberculosis Indacaterol Effectiveness in COPD Patients with Tuberculosis History (INFINITY) GDCT## NCT##, CQAB##BKR## Respiratory Chronic Obstructive Pulmonary Disease (COPD),

  • Respiratory Disease
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Clinical Trial profile. 1747 Trial Title

Tuberculosis and Lung Disease ## Feb 2012 ## ## ## Trial Identifier Secondary ID(s) Therapy Area Indication(s) Trial Status Trial Phase Study Type Drug(s)/ Molecule(s) Sponsor(s) Collaborator(s) Estimated Start Date # of Subjects Planned # of Location(s) # of Investigator(s) Clinical Tria

  • Respiratory Disease
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • 1.2 MARKET DEFINITION
  • ROW: RESPIRATORY DIAGNOSTICS MARKET SIZE, BY DISEASE, 2014-2021 (USD MILLION)

RESPIRATORY DIAGNOSTICS MARKET SIZE FOR TUBERCULOSIS, BY REGION, 2014-2021 (USD MILLION) IN 2016, NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS.

  • Diagnostics
  • Hospital
  • Respiratory Disease
  • Market Size
  • Alere Inc.

This system will help us speed up the process of finding treatments and vaccines for human tuberculosis, an infection that kills ##. ## million people per year. "

  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • United Kingdom
  • GlobalData's company
  • CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - PIPELINE BY MICROBION CORP, H1 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2017 (CONTD..9), H1 2017
  • Respiratory Disease
  • Respiratory Treatment
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • Clinical Trial
  • Pharmaceutical
  • Pulmonary Delivery
  • Respiratory Disease
  • GlobalData's company
  • Clinical Trial
  • Respiratory Disease
  • United States
  • Company Financials
  • GlobalData's company

Phase II data and orphan drug designation from FDA and EMA for non tuberculosis mycobacterium is expected in ##H 2017.

  • Respiratory Disease
  • United States
  • World
  • Product Initiative
  • Cempra, Inc.

SMALL MOLECULE FOR COPD, CYSTIC FIBROSIS, PNEUMONIA AND PULMONARY TUBERCULOSIS - DRUG PROFILE MICROBION CORP SMALL MOLECULE FOR COPD, CYSTIC FIBROSIS, PNEUMONIA AND PULMONARY TUBERCULOSIS SMALL MOLECULE IS UNDER DEVELOPMENT FOR TREATMENT OF PULMONARY TUBERCULOSIS, PNEUMONI

  • Respiratory Disease
  • United States
  • Company
  • Product Initiative
  • Galapagos NV

Bronchiectasis Global Clinical Trials Review, H##, 2016 Reference Code: GDHC##CTIDB Publication Date: DEC 2016 LIST OF TABLES LIST OF FIGURES Bronchiectasis Global Clinical Trials Review, H##, 2016 outlines clinical trials in Bronchiectasis.

  • Pharmaceutical
  • Respiratory Disease
  • World
  • Product Initiative
  • Pulmaquin group

These proteins are used for the treatment of various diseases such as asthma and COPD, diabetes, angina pectoris, cancer, bone disorders, migraine, and tuberculosis.

  • Respiratory Disease
  • Asia
  • World
  • Market Size
  • AstraZeneca PLC
  • ALPHA-1 PROTEINASE INHIBITOR (HUMAN) SECOND GENERATION - DRUG PROFILE

IT IS IN DISCOVERY STAGE OF DEVELOPMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTIONS.

  • Cystic Fibrosis
  • Respiratory Disease
  • United States
  • Product Initiative
  • Galapagos NV

The drug candidate is in Phase III stage of development for the treatment of bronchiolitis and in Phase II for chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and non tuberculosis mycobacterium in CF patients.

  • Respiratory Disease
  • United States
  • World
  • Product Initiative
  • Cempra, Inc.

Nasacort Allergy ##HRTM should not be used when allergic to any of its ingredients, and in patients with active or dormant tuberculosis, or untreated fungal, bacterial and viral infection.

  • Allergy Drug
  • Pharmaceutical
  • Respiratory Disease
  • Therapy
  • Pfizer Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017 (CONTD..9), H2 2017

IT WAS ALSO UNDER DEVELOPMENT FOR TUBERCULOSIS.

  • Respiratory Disease
  • United States
  • Product Initiative
  • Social Conditions
  • AstraZeneca PLC
  • Clinical Trial
  • Respiratory Disease
  • Therapy
  • United States
  • GlobalData's company

Griffith is the Chief of the Medical Staff at the Texas Center for Infectious Disease (TCID) at San Antonio, Texas, and the Assistant Medical Director for the Heartland National Tuberculosis Center, which is also based at TCID in San Antonio, TX.

  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative
  • Pulmaquin group
  • ALPHA-1 PROTEINASE INHIBITOR (HUMAN) SECOND GENERATION - DRUG PROFILE

Griffith is the Chief of the Medical Staff at the Texas Center for Infectious Disease (TCID) at San Antonio, Texas, and the Assistant Medical Director for the Heartland National Tuberculosis Center, which is also based at TCID in San Antonio, TX.

  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative
  • Pulmaquin group